Ticker
LLY

Price
586.46
Stock movement up
+13.23 (2.31%)
Company name
Eli Lilly and Company
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
558.51B
Ent value
595.16B
Price/Sales
19.57
Price/Book
51.83
Div yield
0.77%
Div growth
13.51%
Growth years
7
FCF payout
63.44%
Trailing P/E
89.44
Forward P/E
50.08
PEG
6.79
EPS growth
17.40%
1 year return
88.21%
3 year return
57.22%
5 year return
40.87%
10 year return
27.37%
Last updated: 2023-09-08
Eli Lilly stock outperformed my previous expectations due to its solid execution and growth. Find out why investors must not fall prey to chasing LLY now.
September 20, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
September 19, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share4.52
Dividend yield0.77%
Payout frequencyQuarterly
Maximum yield2.66%
Average yield1.73%
Minimum yield0.77%
Discount to avg yield-123.89%
Upside potential-55.33%
Yield as % of max yield29.00%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield0.77%
Current yield distribution99.92%
Yield at 100% (Min)0.77%
Yield at 90%1.17%
Yield at 80%1.27%
Yield at 50% (Median)1.77%
Yield at 20%2.20%
Yield at 10%2.30%
Yield at 0% (Max)2.66%

Dividend per share

Loading...
Dividend per share data
Years of growth7 years
CCC statusDividend Challenger
Dividend per share4.52
Payout frequencyQuarterly
Ex-div date14 Aug 2023
EPS (TTM)6.57
EPS (1y forward)11.71
EPS growth (5y)17.40%
EPS growth (5y forward)13.18%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
LLYS&P500
DGR MR15.31%8.78%
DGR TTM15.30%8.57%
DGR 3 years14.96%4.00%
DGR 5 years13.51%5.65%
DGR 10 years7.18%7.37%
DGR 15 years5.73%5.83%
Time since last change announced284 days
EPS growth (5y)17.40%
EPS growth (5y forward)13.18%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM56.62%63.44%
Average--
Forward38.60%-
Loading...
AD

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E89.44
Price to OCF78.84
Price to FCF100.21
Price to EBITDA66.23
EV to EBITDA70.57

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales19.57
Price to Book51.83
EV to Sales20.85
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
September 15, 2023

iO Charts is a Seeking Alpha partner

Eli Lilly's stock benefits from strong results and Novo Nordisk's successful weight loss drug, Wegovy. Read here to know why we recommend a buy on LLY stock.
September 14, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count952.35M
EPS (TTM)6.57
FCF per share (TTM)5.87

Income statement

Loading...
Income statement data
Revenue (TTM)28.54B
Gross profit (TTM)21.91B
Operating income (TTM)8.11B
Net income (TTM)6.24B
EPS (TTM)6.57
EPS (1y forward)11.71

Margins

Loading...
Margins data
Gross margin (TTM)76.77%
Operating margin (TTM)28.43%
Profit margin (TTM)21.88%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash2.07B
Net receivables8.56B
Total current assets18.03B
Goodwill4.07B
Intangible assets7.21B
Property, plant and equipment0.00
Total assets49.49B
Accounts payable1.93B
Short/Current long term debt16.24B
Total current liabilities17.14B
Total liabilities38.71B
Shareholder's equity10.78B
Net tangible assets-629.80M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)7.08B
Capital expenditures (TTM)2.00B
Free cash flow (TTM)5.57B
Dividends paid (TTM)3.54B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity57.95%
Return on Assets12.62%
Return on Invested Capital23.12%
Cash Return on Invested Capital20.63%
Loading...
AD

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open572.33
Daily high587.52
Daily low571.60
Daily Volume3.65M
All-time high586.46
1y analyst estimate380.75
Beta0.35
EPS (TTM)6.57
Dividend per share4.52
Ex-div date14 Aug 2023
Next earnings date2 Nov 2023

Downside potential

Loading...
Downside potential data
LLYS&P500
Current price drop from All-time high-1.07%-5.59%
Highest price drop-74.70%-56.47%
Date of highest drop5 Mar 20099 Mar 2009
Avg drop from high-30.92%-11.49%
Avg time to new high31 days13 days
Max time to new high4567 days1805 days
Eli Lilly and Company (NYSE:NYSE:LLY) Morgan Stanley 21st Annual Global Healthcare Conference 2023 Call September 11, 2023 2:55 PM ETCompany ParticipantsDan Skovronsky - Chief Scientific...
September 11, 2023

iO Charts is a Seeking Alpha partner

Eli Lilly's stock is hitting new all-time highs as earnings continue to grow at a rapid rate. Read more about LLY stock here.
September 11, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
LLY (Eli Lilly and Company) company logo
Marketcap
558.51B
Marketcap category
Large-cap
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Employees
39000
SEC filings
CEO
David Ricks
Country
USA
City
Indianapolis
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
September 10, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
September 8, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
September 7, 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
September 2, 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
August 31, 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
August 29, 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
August 27, 2023
Eli Lilly (LLY) and Novo Nordisk's (NVO) current valuations are not sustainable and there exist numerous adverse factors. Learn what are those adverse factors.
August 24, 2023
Eli Lilly is in an epic bubble, pricing in all growth through 2036 and trading at almost 60X forward earnings. Find out another dividend aristocrat pick to buy.
August 23, 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
August 22, 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
August 21, 2023
Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.
August 15, 2023
iO Charts is a Seeking Alpha partnerNext page